The Hidden Price of Permission: Why Markets and Alliances Run on the Same Logic

The real question is not who is in charge, but who can say yes

What do prescription drug prices and NATO enlargement have in common? At first glance, almost nothing. One belongs to the everyday machinery of healthcare, where patients discover at the pharmacy counter that a medication costs far more than expected. The other belongs to high diplomacy, where leaders negotiate the fate of military alliances under pressure from war, geography, and history.

Yet both reveal the same unsettling truth: modern systems are often governed less by open competition than by bottlenecks of permission. In one case, a patient, doctor, pharmacist, insurer, and intermediary all touch the same transaction, but one opaque actor can tilt the price. In the other, a sovereign state can be ready for membership, but a single holdout can stall the entire alliance. The deeper lesson is not simply that power concentrates. It is that power in complex systems often hides in the ability to delay, redirect, or condition a yes.

That is the real tension connecting these seemingly distant worlds: when a system becomes interdependent, the decisive actor is not always the most visible one, but the one positioned at the chokepoint.

---

From exchange to gatekeeping: how complexity creates leverage

In a simple market, value flows through a transparent chain. A buyer wants a product, a seller offers it, and price reflects a relatively direct negotiation between supply and demand. In a simple alliance, membership depends on broad agreement and a few clearly defined criteria. But modern life rarely stays simple for long.

Prescription drug markets are layered with middlemen, rebates, formularies, contracting rules, and confidential incentives. That complexity creates room for actors who do not manufacture the medicine or consume it, but still shape what the patient pays. The result is not just inefficiency. It is a structural opportunity for gatekeeping as a business model.

Geopolitical alliances can become similarly layered. NATO does not enlarge by abstract principle alone. It enlarges through unanimous consent, strategic timing, domestic politics, and bargaining among existing members. That makes expansion possible, but only through a narrow corridor of approval. When a key member withholds consent, the whole architecture pauses. The system is not broken, exactly. It is functioning as designed, which is precisely what makes it so powerful and so frustrating.

This is the paradox: the more interconnected a system becomes, the more it depends on trusted intermediaries and permission points. But every permission point is also a point of leverage.

Think of a modern airport. Security is meant to protect everyone, but if too many travelers must pass through too few checkpoints, the checkpoint itself becomes the experience. It can be efficient, arbitrary, reassuring, or infuriating, depending on who controls it. The same is true in drug pricing and alliance politics. The chokepoint does not merely facilitate exchange. It can reshape the terms of exchange.

---

The chokepoint problem: power without ownership

The most interesting kind of power in the modern world is not ownership. It is control without possession.

A pharmacy benefit manager does not usually own the drug, make the drug, prescribe the drug, or take the drug. But if it controls formulary placement, rebate flows, and the route through which a medication becomes affordable or even accessible, it exerts a form of power that is both indirect and immense. The patient sees a price. The doctor sees a treatment option. The employer sees a health plan. Behind all of that may be a set of incentives that reward obscurity more than clarity.

A similar dynamic appears in alliance diplomacy. Turkey did not need to rewrite NATO’s charter, defeat Sweden militarily, or disprove Sweden’s strategic value. It only needed to occupy the narrow legal and political position that allowed it to say no until the right concessions, signals, and timings emerged. That is not raw domination. It is structural leverage.

This matters because leverage of this kind tends to look legitimate from the inside. The gatekeeper can say, “I am following the rules.” And often that is true. But rules are not neutral just because they are formal. A rule requiring unanimous agreement, or a contracting system that hides the final price from the end user, can create a world where the rational behavior of each participant produces an irrational outcome for everyone else.

When a system rewards control over the route more than contribution to the outcome, it stops optimizing for value and starts optimizing for bottlenecks.

That sentence applies to both stories. In healthcare, the route from manufacturer to patient is so fragmented that the middle can become more profitable than the end value. In diplomacy, the route from candidate to member can become so contingent that national security is shaped by bargaining leverage rather than strategic fit. The details differ, but the mechanism is the same.

---

Why this kind of power is so hard to see, and even harder to fix

The deepest danger of chokepoint power is that it is rarely experienced as a single dramatic abuse. It appears as friction. It appears as delay. It appears as confusing paperwork, shifting explanations, last minute conditions, or a negotiation that must be revisited one more time.

That is why people often underestimate it. Humans are trained to notice visible coercion, not invisible rerouting. If a soldier closes a border, or a government imposes a formal veto, the power is obvious. But if a pricing structure quietly raises the cost of a needed drug, or if an alliance decision is held hostage to unrelated grievances, the harm is distributed and harder to narrate.

This gives chokepoint power three advantages:

1. Plausible deniability: the gatekeeper can point to process rather than outcome.
2. Fragmented accountability: every actor can blame another link in the chain.
3. Negotiation fatigue: outsiders eventually accept the bottleneck as normal.

That last point is especially important. Over time, people adapt to constrained systems by lowering expectations. Patients stop asking why a medication is so expensive and simply search for coupons, prior authorizations, and workaround plans. Smaller states or applicant members stop asking whether alliance decisions are being made on principle and instead focus on the art of appeasing whoever has veto power.

The result is a politics of resignation. Once resignation sets in, the chokepoint no longer needs to justify itself. It only needs to persist.

This is why the best reform efforts fail when they focus only on visible prices or visible declarations. In drug markets, lowering the sticker price means little if the hidden rebate structure still distorts incentives. In international politics, celebrating a new agreement means little if the underlying rule set still allows one actor to paralyze collective action at will. The surface event is not the system.

---

A better mental model: the difference between value creation and route control

The most useful way to connect these stories is to separate two kinds of power:

• Value creation: making something useful, secure, or desirable.
• Route control: deciding how, when, and on what terms that value reaches others.

In healthy systems, route control serves value creation. A pharmacist helps dispense medication safely. A treaty process helps ensure that alliance membership is meaningful. But in distorted systems, route control becomes an end in itself. The intermediary begins to profit from being unavoidable rather than from improving the underlying value.

This is a subtle but crucial distinction. An organization can be indispensable without being extractive. The problem begins when indispensability is monetized or weaponized.

A useful analogy is the road toll. A toll can maintain a bridge, fund infrastructure, and allocate scarce capacity. But if every route into a city is controlled by separate toll collectors, each able to raise prices independently, transport costs stop reflecting distance or service quality and start reflecting access to passage. The traveler pays not for the journey, but for the privilege of not being blocked.

That is the hidden logic behind both the pharmacy benefit manager debate and the NATO accession drama. In each case, the decisive question is not simply who produces the good, or who wants membership. It is who controls passage through the institutional maze.

Once you see this, many other systems snap into focus. Hiring platforms, app stores, supply chains, academic publishing, social media distribution, even visa regimes. Wherever access depends on a few nodes, those nodes can drift from facilitators into toll collectors. The system remains formally open, but practically curated.

The modern world is less ruled by ownership than by friction design.

That phrase may sound technical, but it captures a profound shift. Whoever can add, remove, or obscure friction can shape behavior without ever issuing an explicit command.

---

What these cases teach about reform: transparency is not enough

The obvious response to opaque systems is transparency. Reveal the prices. Disclose the terms. Make the bargaining visible. Transparency matters, but it is not sufficient. A transparent bottleneck is still a bottleneck.

If a pharmacy benefit manager’s role is fully disclosed but the contracting structure still rewards higher list prices and hidden rebates, the patient may know more and still pay too much. If an alliance’s decision process is fully public but unanimity still enables long delays or leverage unrelated to shared security, everyone may understand the game and still be trapped inside it.

That means meaningful reform has to ask a harder question: does the structure align permission with purpose?

Here is a practical test. For any system, ask three questions:

• Who creates the value?
• Who controls access to that value?
• Who benefits when access is delayed, obscured, or complicated?

If the same actor answers all three, the system may be efficient. If different actors answer them, the arrangement may be stable. But if the actor controlling access is rewarded for making access harder, the system is likely extractive.

This framework helps explain why reforms in complex systems so often disappoint. They target the visible interface instead of the hidden incentive. They clean the window but leave the gears untouched.

A healthier prescription drug market would reduce incentives to profit from confusion, not just expose confusion. A healthier alliance process would preserve seriousness and standards while limiting the ability of one member to convert strategic relevance into perpetual leverage. In both cases, the goal is the same: make gatekeeping earn its place.

That does not mean abolishing intermediaries or eliminating consensus. Some gates are necessary. The question is whether the gate is serving the road or taxing it.

---

Key Takeaways

• Look for chokepoints, not just headlines. The most important power in a system may belong to whoever controls the route, not whoever creates the value.
• Separate transparency from incentives. Knowing how a system works is not enough if the structure still rewards delay, opacity, or leverage.
• Ask who benefits from friction. When confusion or delay is profitable, the system is likely optimizing for extraction instead of service.
• Evaluate permission rules by purpose. A veto, a rebate, or a gate may be legitimate only if it improves the underlying outcome rather than merely empowering the intermediary.
• Reform the architecture, not just the optics. Real change comes from redesigning incentives and access points, not just publishing more information.

---

The deeper lesson: legitimacy depends on whether permission serves people or power

The same basic drama is playing out in both healthcare and geopolitics. A complex system promises coordination, safety, and scale. But once the system thickens, someone inevitably discovers that the most valuable place to stand is between others and what they want.

That is why these stories matter together. They remind us that institutions do not merely distribute outcomes. They distribute the right to approve outcomes. And once permission itself becomes a source of profit or leverage, the system starts drifting away from its stated mission.

So the next time a price feels arbitrary, or a diplomatic breakthrough seems to hinge on one actor’s reluctant yes, it may be worth asking a larger question: is the system designed to deliver value, or to monetize the path to value?

That question reaches far beyond drugs and alliances. It is one of the defining questions of modern life. The institutions that will endure are not necessarily the ones with the strongest walls or the loudest rhetoric. They are the ones that keep permission tethered to purpose, before gatekeeping becomes the real product.